Ironwood Pharmaceuticals, Inc. (IRWD) Monday said it expects revenue for the fiscal 2023 to be in the range of $435 million - $450 million, same as the previous outlook.
On average, 3 analysts polled by Thomson-Reuters expect the company to report revenue of $444.01 million for the year.
For the year 2024, the company sees revenue between $435 million and $455 million.
Ironwood expects adjusted earnings before interest, taxes, depreciation, and amortization or EBITDA for fiscal 2023 to be a loss of $900 million, while seeing a gain of $150 million for fiscal 2024.
For comments and feedback: editorial@rttnews.com